2023-09-05 08:09:28
The effect of this compound on the incidence of type 2 diabetes among older adults remains uncertain. This study investigated the effect of randomized low-dose treatment on incident diabetes and fasting plasma glucose (FPG) levels among older adults.
Low-dose use (100 mg daily) among adults age 65 and older is associated with a 15% lower risk of developing type 2 diabetes, according to new research to be presented at the European Association for the Study of Diabetes Annual Meeting. Diabetes (EASD) in October in Hamburg (Germany).
The authors, led by Professor Sophia Zoungas, from the Monash University School of Public Health and Preventive Medicine in Melbourne (Australia), state that the results demonstrate that anti-inflammatory agents such as ‘Aspirin’ deserve further study in the prevention of diabetes.
The effect on the incidence of type 2 diabetes among older adults remains uncertain. This study investigated the effect of randomized low-dose treatment on incident diabetes and fasting plasma glucose (FPG) levels among older adults.
The authors did a follow-up study to the ASPREE trial – a double-blind, placebo-controlled trial of ‘Aspirin’, the main results of which were published in the ‘NEJM’ in 2018. The original study showed that ‘Aspirin’ conferred 38% more of risk of major bleeding in older adults without any reduction in the incidence of cardiovascular disease.
The study enrolled community-dwelling individuals 65 years of age or older, and free of cardiovascular disease, independence-limiting physical disability, and dementia. Participants were randomly assigned 1:1 to 100 mg daily ‘Aspirin’ or placebo.
Incident diabetes was defined as self-reported diabetes, initiation of glucose-lowering medication, and/or a fasting plasma glucose (FPG) level of 7.0 mmol/L or higher at annual follow-up visits. Patients with diabetes at baseline were excluded. Computer and statistical models evaluated the effect of ‘Aspirin’ on incident diabetes and FPG levels, respectively.
A total of 16,209 participants (8,086 randomized to ‘Aspirin’ and 8,123 to placebo) were included in the analysis. During a median follow-up of 4.7 years, 995 cases of incident diabetes were recorded (‘Aspirin’: 459, placebo: 536). Compared with placebo, the aspirin-treated group had a 15% reduction in the number of cases of diabetes and a slower rate of rise in blood glucose.
The authors state that “’Aspirin’ treatment reduced incident diabetes and slowed the rise in fasting plasma glucose over time among initially healthy older adults. Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents such as aspirin to prevent type 2 diabetes or improve glucose levels needs further study.”
Professor Zoungas adds: “Findings from previously published ASPREE trials in 2018 showed that ‘Aspirin’ did not prolong healthy independent living, but was associated with a significantly increased risk of bleeding, mainly from the gastrointestinal tract. The main prescribing guidelines now recommend that older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack.
“Although these new findings are of interest, they do not change clinical advice on the use of ‘Aspirin’ in older people at this time,” he concludes. Ana Mera, pharmacist.
#doses #acetylsalicylic #acid #implies #risk #diabetes #study #Health #Medicine